Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 17, 2023 21:00 ET | Source: Bragar Eagel & Squire

Bragar Eagel & Squire, P.C. Is Investigating Fox, Charles River, Provident, and Sarepta and Encourages Investors to Contact the Firm

NEW YORK, April 17, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fox Corporation (NASDAQ:...
January 23, 2020 14:25 ET | Source: Bragar Eagel & Squire

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Cardinal Health, CURO Group, Sarepta, and PG&E Corporation and Encourages Investors to Contact the Firm

NEW YORK, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, is investigating certain officers and directors of Cardinal Health, Inc....
October 15, 2019 20:37 ET | Source: Bragar Eagel & Squire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Valaris, Sarepta Therapeutics, Canada Goose, and Meredith Corporation and Encourages Investors to Contact the Firm

NEW YORK, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Valaris Plc (NYSE: VAL),...
October 09, 2019 08:00 ET | Source: Bragar Eagel & Squire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sarepta Therapeutics, Canada Goose, Meredith Corporation, and MacroGenics and Encourages Investors to Contact the Firm

NEW YORK, Oct. 09, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Sarepta Therapeutics, Inc....
October 02, 2019 21:07 ET | Source: Bragar Eagel & Squire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sarepta Therapeutics, Canada Goose, Meredith Corporation, and MacroGenics and Encourages Investors to Contact the Firm

NEW YORK, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Sarepta Therapeutics, Inc....
September 24, 2019 09:45 ET | Source: Schall Law

INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES, Sept. 24, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sarepta Therapeutics, Inc....
September 17, 2019 10:21 ET | Source: Schall Law

INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES, Sept. 17, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sarepta Therapeutics, Inc....
September 09, 2019 10:56 ET | Source: Schall Law

INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES, Sept. 09, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sarepta Therapeutics, Inc....
March 28, 2017 11:41 ET | Source: Scott + Scott, Attorneys at Law, LLP

Scott+Scott, Attorneys at Law, LLP Announces Investigation of Sarepta Therapeutics, Inc.

NEW YORK, March 28, 2017 (GLOBE NEWSWIRE) -- Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national shareholder and consumer rights litigation firm, announces an investigation into Sarepta...
October 04, 2016 07:01 ET | Source: Summit Therapeutics PLC

Summit to Host Conference Call to Discuss Exclusive License and Collaboration Agreement With Sarepta Therapeutics for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy

OXFORD, United Kingdom, Oct. 04, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...

Next Page keyboard_arrow_right